Imidazopyrimidines, potent inhibitors of p38 MAP kinase

被引：267
|
作者：
Rupert, KC [1 ]
Henry, JR [1 ]
Dodd, JH [1 ]
Wadsworth, SA [1 ]
Cavender, DE [1 ]
Olini, GC [1 ]
Fahmy, B [1 ]
Siekierka, JJ [1 ]
机构：
[1] Johnson & Johnson Pharmaceut Res & Dev, LLC, Drug Discovery, Raritan, NJ 08869 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 03期
关键词：
D O I：
10.1016/S0960-894X(02)01020-X
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：347 / 350
页数：4
相关论文
共 50 条
  • [31] The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
    Wilson, KP
    McCaffrey, PG
    Hsiao, K
    Pazhanisamy, S
    Galullo, V
    Bemis, GW
    Fitzgibbon, MJ
    Garon, PR
    Murcko, MA
    Su, MSS
    CHEMISTRY & BIOLOGY, 1997, 4 (06): : 423 - 431
  • [32] p38 MAP kinase inhibitors: Many are made, but few are chosen
    Dominguez, C
    Powers, DA
    Tamayo, N
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (04) : 421 - 430
  • [33] Critical review of p38 MAP kinase inhibitors: a bioanalytical perspective
    Wong, Philip
    Hsieh, Faye
    Roger Pham
    James, Christopher A.
    BIOANALYSIS, 2012, 4 (01) : 89 - 93
  • [34] Theoretical and experimental design of atypical kinase inhibitors: Application to p38 MAP kinase
    McClure, KF
    Abramov, YA
    Laird, ER
    Barberia, JT
    Cai, WL
    Carty, TJ
    Cortina, SR
    Danley, DE
    Dipesa, AJ
    Donahue, KM
    Dombroski, MA
    Elliott, NC
    Gabel, CA
    Han, SG
    Hynes, TR
    LeMotte, PK
    Mansour, MN
    Marr, ES
    Letavic, MA
    Pandit, J
    Ripin, DB
    Sweeney, FJ
    Tan, D
    Tao, Y
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (18) : 5728 - 5737
  • [35] Dual- action kinase inhibitors influence p38α MAP kinase dephosphorylation
    Stadnicki, Emily J.
    Ludewig, Hannes
    Kumar, Ramasamy P.
    Wang, Xicong
    Qiao, Youwei
    Kern, Dorothee
    Bradshaw, Niels
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2025, 122 (01)
  • [36] New inhibitors of p38 kinase
    Boehm, JC
    Adams, JL
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) : 25 - 37
  • [37] Allosteric p38 kinase inhibitors
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (10) : 1443 - 1448
  • [38] Identification of triazolopyridazinones as potent p38α inhibitors
    Herberich, Brad
    Jackson, Claire
    Wurz, Ryan P.
    Pettus, Liping H.
    Sherman, Lisa
    Liu, Qiurong
    Henkle, Bradley
    Saris, Christiaan J. M.
    Wong, Lu Min
    Chmait, Samer
    Lee, Matthew R.
    Mohr, Christopher
    Hsieh, Faye
    Tasker, Andrew S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1226 - 1229
  • [39] Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors
    Chen, Meng-Hsin
    Fitzgerald, Patricia
    Singh, Suresh B.
    O'Neill, Edward A.
    Schwartz, Cheryl D.
    Thompson, Chris M.
    O'Keefe, Stephen J.
    Zaller, Dennis M.
    Doherty, James B.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) : 2222 - 2226
  • [40] Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase
    Trejo, A
    Arzeno, H
    Browner, M
    Chanda, S
    Cheng, S
    Comer, DD
    Dalrymple, SA
    Dunten, P
    Lafargue, J
    Lovejoy, B
    Freire-Moar, J
    Lim, J
    Mcintosh, J
    Miller, J
    Papp, E
    Reuter, D
    Roberts, R
    Sanpablo, F
    Saunders, J
    Song, K
    Villasenor, A
    Warren, SD
    Welch, M
    Weller, P
    Whiteley, PE
    Zeng, L
    Goldstein, DM
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (22) : 4702 - 4713
12345